American Diabetes Association (ADA) Conference, Boston Reductions in hemoglobin and packed cell volume over 3 years in UKPDS patients with newly-diagnosed type 2 diabetes
Ruth L. Colman, Rury R. Holman
Diabetes 2015;64:1:A440
51st Annual Meeting of the European Association for the Study of Diabetes, Stockholm Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus
N. Sattar, D. Preiss , D. Blom , C.S. Djedjos, M. Elliott , A. Pellacani, S.M. Wasserman, M. Koren, R. Holman
Diabetelogia 2015;58:(Suppl 1):S79 [Abstract]
51st Annual Meeting of the European Association for the Study of Diabetes, Stockholm Patient characteristics are associated with treatment response to second line glucose lowering therapy: a MASTERMIND study
B.M. Shields, M. Lonergan, J. Dennis, A. Jones, L. Rogers, M. Weedon, L. Donnelly, R. Holman, W. Henley, E. Pearson, A. Hattersley
Diabetelogia 2015;58:(Suppl 1):S405 [Abstract]
Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ
Tel: +44 (0)1865 857242 Email: dtu@dtu.ox.ac.uk